Barros PP, Righetti G., and Sá L. (2025). Pricing Mechanisms for Multi-Indication Drugs. Available at https://papers.ssrn.com/abstract=5374679. Under review
Gamba S., Pertile P., and Righetti G. (2025). Pricing Without Borders: Spillovers of External Reference Pricing in Pharmaceutical Regulation. Available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=5381635. Submitted
Barros PP, Righetti G., and Sá L. (2025). On the Long-Term Effects of Most Favored Nation Drug Pricing.
Righetti G. (2024). The Impact of Amnog Reform in Germany On Pharmaceutical Prices. Available at https://ssrn.com/abstract=4828807. Under review
"External Reference Pricing with Confidential Discounts?" with P. Pertile
"New Accountability Relationship in the Public Healthcare System: The Effect of Information Release in South Africa", with Alessandro Barbazeni and Earle J. du Plooy
"Mind the Gap: Toward an Equity-Conscious Pricing System for Multi-Indication Drugs ", with P.P. Barros, B. Haon, L. Sá, and L. Rochaix
"The Clinical Trial Balloon: How Strategic Evidence-Shaping Drives Drug Prices” with P.P. Barros, A. Gentilini, M. Miraldo, C. Santos
“Losing Control: Patient Organizations and Retention in Randomized Clinical Trials”
“The Price of Choice: How Private Hospital Access Shapes Out-of-Pocket Spending” with P. Bertoli and C. Fertonani
Righetti, G. (2026). Regulação Farmacêutica em Contexto Internacional: Implicações para o SNS. Nova SBE, Social Equity Initiative – Health Economics Chair